Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 401

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 401
---
 accordance with the Assignment Agreements, the $ of restricted cash became unrestricted in October 2024. As of December 31, 2024, there was restricted cash on the Company’s Consolidated Balance Sheet. As of December 31, 2023, the Company had $ of restricted cash related to its previous lease (which was terminated in December 2023 and became unrestricted in January 2024) in current assets and $ of restricted cash related to the New Lease in long-term assets.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.

| ​                                                                                                    | ​ 
 ​ | ​ |                 ​ 
 December 31, 2024 | ​ | ​ |                 ​ 
 December 31, 2023 |
|:-----------------------------------------------------------------------------------------------------|:--|:--|------------------:|:--|:--|------------------:|
| Cash and cash equivalents                                                                            | ​ | $ |            37,903 | ​ | $ |            51,775 |
| Restricted cash, current assets                                                                      | ​ |   |                 — | ​ |   |               408 |
| Restricted cash, long-term assets                                                                    | ​ |   |                 — | ​ |   |             1,500 |
| Total cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows | ​ | $ |            37,903 | ​ | $ |            53,683 |

F-75

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in thousands, except share and per share data)

9 .Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

| ​                                   | ​ 
 ​ | ​ |                 ​ 
 December 31, 2024 | ​ | ​ |                 ​ 
 December 31, 2023 |
|:------------------------------------|:--|:--|------------------:|:--|:--|------------------:|
| Accounts payable                    | ​ | $ |             1,434 | ​ | $ |            11,583 |
| Accrued research projects           | ​ |   |                64 | ​ |   |             4,343 |
| Accrued compensation and benefits   | ​ |   |               565 | ​ |